|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ADC, mainly ADC<sub>oscillating</sub> , increased in the group of nodules with intermediate malignancy (ADC<sub>pulsed</sub> : 0.75 ± 0.25 × 10<sup>-3</sup> mm<sup>2</sup> /s vs. 0.64 ± 0.07 × 10<sup>-3</sup> mm<sup>2</sup> /s in benign nodules, P = 0.025; ADC<sub>oscillating</sub> : 0.81 ± 0.20 × 10<sup>-3</sup> mm<sup>2</sup> /s vs. 0.65 ± 0.13 × 10<sup>-3</sup> mm<sup>2</sup> /s, P = 0.0008) and ADC<sub>pulsed</sub> decreased in the group of progressed hepatocellular carcinomas (ADC<sub>pulsed</sub> : 0.60 ± 0.08 × 10<sup>-3</sup> mm<sup>2</sup> /s, P = 0.042; ADC<sub>oscillating</sub> : 0.68 ± 0.08 × 10<sup>-3</sup> mm<sup>2</sup> /s, P = 0.1).
|
31507025 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although the CT findings are nonspecific, typical MR imaging findings, including those on the ADC map and dynamic contrast-enhanced MR imaging, may be helpful for differentiating glomangiopericytomas from other hypervascular tumors in the head and neck.
|
31806599 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor ADC and tumor size on MRI may be useful parameters in association with pathologic upgrading in biopsy-proven grade I endometrial cancer.
|
31206949 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor segmentation was done on T2-images and transferred to b800-images and ADC maps, after which quantitative and four semantic features were extracted.
|
31431368 |
2020 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
ADC, mainly ADC<sub>oscillating</sub> , increased in the group of nodules with intermediate malignancy (ADC<sub>pulsed</sub> : 0.75 ± 0.25 × 10<sup>-3</sup> mm<sup>2</sup> /s vs. 0.64 ± 0.07 × 10<sup>-3</sup> mm<sup>2</sup> /s in benign nodules, P = 0.025; ADC<sub>oscillating</sub> : 0.81 ± 0.20 × 10<sup>-3</sup> mm<sup>2</sup> /s vs. 0.65 ± 0.13 × 10<sup>-3</sup> mm<sup>2</sup> /s, P = 0.0008) and ADC<sub>pulsed</sub> decreased in the group of progressed hepatocellular carcinomas (ADC<sub>pulsed</sub> : 0.60 ± 0.08 × 10<sup>-3</sup> mm<sup>2</sup> /s, P = 0.042; ADC<sub>oscillating</sub> : 0.68 ± 0.08 × 10<sup>-3</sup> mm<sup>2</sup> /s, P = 0.1).
|
31507025 |
2020 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
PDGFRβ was an independent predictor of poor survival in the overall Norwegian cohort and an independent predictor of increased survival in the ADC (adenocarcinoma) subgroup of the Swedish cohort.
|
31308421 |
2019 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We analyzed positron emission tomography-computed tomography (PET-CT) in patients with stage III non-small-cell lung cancer (NSCLC) undergoing concurrent chemoradiotherapy (CRT) to examine the prognostic value of PET-CT parameters according to histologic subtypes (squamous cell carcinoma [SqCC] and adenocarcinoma [ADC]).
|
30266585 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In univariate analysis, lower ADC, axial diffusivity, and radial diffusivity were associated with malignancy (OR = 0.37-0.42 per 1-SD increase, p < 0.001 for each), as was higher FA (OR = 1.45, p = 0.007).
|
31484577 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To determine if PSAD, PSADtz, and ADC values improve the accuracy of PI-RADS v2 and identify men whose concurrent systematic biopsy detects clinically significant cancer on areas without mpMRI visible lesions.
|
31136112 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, statistically significant differences were found between the noncancer and cancer groups in T2 values and ADC values (diff TEs) (P = 0.000).
|
31218387 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Background</b>: MicroRNAs (miRNAs) are becoming recognized as novel diagnostic and prognostic biomarkers in several malignancies, including non-small-cell lung cancer (NSCLC). miR-25 is overexpressed in small cell lung cancer (SCLC) and NSCLC tissues, and high miR-25 expression is associated with poorer overall survival of women with lung ADC.
|
30919763 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DW MRI is a promising non-invasive MRI technique used to differentiate recurrent/residual head and neck malignancies from posttreatment changes based on ADC values.
|
31422219 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ADC products based on the non-internalizing 1959 antibody may be useful for the treatment of several human malignancies, as the cognate antigen is abundantly expressed and secreted by several cancers, while being present at low levels in most normal adult tissues.
|
30553852 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
There are no previous reports on the impact of AZIN2 expression in human cancer.
|
30768610 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The 10th percentile ADC obtained from ultrahigh b-value DWI performed better for differentiating TZ cancer from BPH.
|
30475249 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The current study aims to explore the possible anti-lung carcinoma activity of ADC as well as the underlying mechanisms by which ADC exerts its actions in NSCLC.
|
30870998 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Besides, patients with high PD-L1 expression had shorter OS in NSCLC (P=0.000), ADC (P=0.000), SCC (P=0.353) and LELC (P=0.810), while no significant difference was observed in SCLC (P=0.000).
|
31555517 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PET-CT provided different prognostic implications between SqCC and ADC in patients with locally advanced NSCLC receiving radical CRT.
|
30266585 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Background</b>: MicroRNAs (miRNAs) are becoming recognized as novel diagnostic and prognostic biomarkers in several malignancies, including non-small-cell lung cancer (NSCLC). miR-25 is overexpressed in small cell lung cancer (SCLC) and NSCLC tissues, and high miR-25 expression is associated with poorer overall survival of women with lung ADC.
|
30919763 |
2019 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HPV was detected in 16 and 10.2% of ADC and squamous cell carcinoma.
|
31157548 |
2019 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed positron emission tomography-computed tomography (PET-CT) in patients with stage III non-small-cell lung cancer (NSCLC) undergoing concurrent chemoradiotherapy (CRT) to examine the prognostic value of PET-CT parameters according to histologic subtypes (squamous cell carcinoma [SqCC] and adenocarcinoma [ADC]).
|
30266585 |
2019 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment of GBM with BVZ leads to a decrease of ADC values in areas of pre-treatment T1-CE/FLAIR signal hyperintensity to levels of comparable with normal brain tissue.
|
29733920 |
2019 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Average ADC values for diffuse midline gliomas were 1.28 × 10<sup>-3</sup>mm<sup>2</sup>/s (95% CI, 1.21-1.34) and 0.86 × 10<sup>-3</sup>mm<sup>2</sup>/s (95% CI, 0.69-1.01) for hemispheric glioblastomas with <i>P</i> < .05.
|
31694820 |
2019 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The exact significance of ADC maps in GBM has yet to be elaborated.
|
31229576 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Multivariate analysis revealed that reverse target sign on hepatobiliary phase in FNHs (p = 0.009), iso or hyperintensity on ADC map in FNHs and HCAs (p = 0.009, < 0.001, respectively), central hypointensity on arterial phase in NETs (p = 0.001), hepatobiliary target sign in ICCs (p = 0.002), the presence of septum and capsule in HCCs (all p < 0.001) were significant independent features of each tumor group over other tumor groups.
|
31134313 |
2019 |